John Feeney v. Morfin Capital Group LLC and Medone Texas MSO, LLC

CourtCourt of Appeals of Texas
DecidedAugust 20, 2024
Docket05-22-01375-CV
StatusPublished

This text of John Feeney v. Morfin Capital Group LLC and Medone Texas MSO, LLC (John Feeney v. Morfin Capital Group LLC and Medone Texas MSO, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
John Feeney v. Morfin Capital Group LLC and Medone Texas MSO, LLC, (Tex. Ct. App. 2024).

Opinion

Affirmed and Opinion Filed August 20, 2024

S In The Court of Appeals Fifth District of Texas at Dallas No. 05-22-01375-CV

JOHN FEENEY, Appellant V. MORFIN CAPITAL GROUP LLC AND MEDONE TEXAS MSO, LLC, Appellees

On Appeal from the 162nd Judicial District Court Dallas County, Texas Trial Court Cause No. DC-22-07016

MEMORANDUM OPINION Before Justices Goldstein, Garcia, and Miskel Opinion by Justice Goldstein Appellant John Feeney appeals the trial court’s denial of his special

appearance. In four issues, Feeney contends that the trial court erred because

(1) appellees Morfin Capital Group LLC (Morfin Capital) and MedOne Texas MSO,

LLC (MedOne) failed to sufficiently plead and prove jurisdictional facts; (2) Feeney

lacked sufficient minimal contacts with Texas; (3) the fiduciary shield doctrine

precluded the trial court’s exercise of personal jurisdiction; and (4) the trial court’s

exercise of personal jurisdiction did not comport with traditional notions of fair play and substantial justice. We affirm in this memorandum opinion. See TEX. R. APP. P.

47.2(a).

BACKGROUND

On June 24, 2022, Morfin Capital and MedOne, both owned by Ryan Morfin,

filed this lawsuit against Feeney and three other defendants: One Health Medical

Systems LLC (One Health), David J. Ross, and Roger Farahmand. The original

petition alleged that Feeney, Ross, and Farahmand were “the owners or principals”

of One Health and, in those roles, represented to MedOne that One Health had

sufficient financial resources to purchase MedOne’s assets. The petition further

alleged that, based on those representations, MedOne entered into an asset purchase

agreement (APA) with One Health, which the latter could not perform because it

lacked the financial resources to buy MedOne’s assets. The petition asserted a claim

for breach of contract against One Health and a claim for fraudulent inducement

against Feeney, Ross, and Farahmand. Of the four defendants, Feeney was the only

one identified by the original petition as a non-Texas resident.

On August 28, 2022, Feeney filed a special appearance, asserting that he was

a Wisconsin resident who had “no meaningful contacts with Texas[.]” In the special

appearance, Feeney complained that the original petition failed to include any factual

allegations about his contacts with Texas sufficient for the trial court to exercise

personal jurisdiction over him. In an attached declaration, Feeney testified that he

had never lived in Texas, had no property in Texas, and was “not a member or

–2– manager for any of the . . . limited liability companies named as parties to this

lawsuit.” Feeney scheduled an oral hearing on his special appearance for September

26, 2022.

On September 21, 2022, Morfin Capital and MedOne filed their first amended

petition, adding additional jurisdictional facts about Feeney. Namely, the first

amended petition contained an allegation that Feeney was the CEO of One Health.

It also alleged in June 2018, “Ross, Farahmand, and Feeney met with [Morfin]

several times in Texas” and “told [Morfin] that One Health had sufficient finances

to complete an acquisition of MedOne’s assets.” At the September 26 hearing, the

trial court noted that this specific allegation was not contained in appellees’ original

petition and that Feeney had not had the opportunity to adduce evidence to controvert

the allegation. The trial court therefore recessed the hearing and directed Feeney’s

counsel to “amend your special appearance in order to include whatever you believe

counters the statements in [appellees’] first amended petition.”

On November 2, 2022, Feeney filed his first amended special appearance.

Attached to the special appearance was Feeney’s unsworn declaration. In paragraph

3 of the declaration, Feeney testified that he had not “committed any torts in the State

of Texas.” Feeney scheduled a hearing on the special appearance for December 2.

On November 23, appellees filed their second amended petition. On November 29,

appellees filed a response to the special appearance and objection to Feeney’s

declaration. Specifically, appellees objected to paragraph 3 of Feeney’s declaration

–3– on the ground that it was conclusory. After the scheduled hearing, the trial court

entered an order sustaining appellees’ objection and denying Feeney’s special

appearance. This appeal followed.

DISCUSSION

I. STANDARD OF REVIEW

We review a trial court’s exercise of personal jurisdiction over a nonresident

defendant de novo. Steward Health Care Sys. LLC v. Saidara, 633 S.W.3d 120, 125

(Tex. App.—Dallas 2021, no pet.) (en banc). When a trial court does not issue

findings of fact and conclusions of law with its special appearance ruling, all facts

necessary to support the judgment and supported by the evidence are implied. Id.

“When the appellate record includes the reporter’s and clerk’s records, however,

these implied findings are not conclusive and may be challenged for legal and factual

sufficiency in the appropriate appellate court.” Id. at 125–26. “When the relevant

facts in a case are undisputed, an appellate court need not consider any implied

findings of fact and considers only the legal question of whether the undisputed facts

establish Texas jurisdiction.” Id. at 126.

II. APPLICABLE LAW

“A court must have personal jurisdiction over a defendant to issue a binding

judgment.” LG Chem Am., Inc. v. Morgan, 670 S.W.3d 341, 346 (Tex. 2023). Trial

courts may exercise personal jurisdiction over a nonresident defendant if it is

(1) authorized by the Texas long-arm statute, and (2) consistent with federal due-

–4– process guarantees. Id. (internal citations omitted). The Texas long-arm statute

“reaches as far as the federal constitutional requirements for due process will allow.”

State v. Volkswagen Aktiengesellschaft, 669 S.W.3d 399, 412 (Tex. 2023). For

example, the Texas long-arm statute permits a trial court to exercise personal

jurisdiction over a defendant who “does business in this state,” which is defined to

include a nonresident defendant who “commits a tort in whole or in part in this state.”

LG Chem, 670 S.W.3d at 346 (quoting TEX. CIV. PRAC. & REM. CODE § 17.042(2)).

“However, allegations that a tort was committed in Texas do not necessarily satisfy

the United States Constitution.” Old Republic Nat’l Title Ins. Co. v. Bell, 549 S.W.3d

550, 559 (Tex. 2018). To establish personal jurisdiction over a nonresident, federal

due process requires that the nonresident must have “certain minimum contacts with

[the forum state] such that the maintenance of the suit does not offend ‘traditional

notions of fair play and substantial justice.’” Id. (quoting Int’l Shoe Co. v. State of

Wash., Office of Unemployment Comp. & Placement, 326 U.S. 310, 316 (1945)).

The minimum-contacts inquiry is a “forum-by-forum” or “sovereign-by-sovereign”

analysis that “examines the nature and extent of the defendant’s relationship to the

forum to determine whether the defendant is amenable to general or specific

jurisdiction.” Volkswagen, 669 S.W.3d at 412; see LG Chem, 670 S.W.3d at 347

(“There are two kinds of personal jurisdiction: ‘general (sometimes called all-

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Keeton v. Hustler Magazine, Inc.
465 U.S. 770 (Supreme Court, 1984)
Moki Mac River Expeditions v. Drugg
221 S.W.3d 569 (Texas Supreme Court, 2007)
Spir Star AG v. Kimich
310 S.W.3d 868 (Texas Supreme Court, 2010)
ACS Investors, Inc. v. McLaughlin
943 S.W.2d 426 (Texas Supreme Court, 1997)
Petrie v. Widby
194 S.W.3d 168 (Court of Appeals of Texas, 2006)
Eberstein v. Hunter
260 S.W.3d 626 (Court of Appeals of Texas, 2008)
Michiana Easy Livin' Country, Inc. v. Holten
168 S.W.3d 777 (Texas Supreme Court, 2005)
Holloway v. Skinner
898 S.W.2d 793 (Texas Supreme Court, 1995)
Sebastian Lombardo v. Shouvik Bhattacharyya
437 S.W.3d 658 (Court of Appeals of Texas, 2014)
Kaye/Bassman International Corp. v. Pankaj Dhanuka and Kishore Saraogi
418 S.W.3d 352 (Court of Appeals of Texas, 2013)
Julie Stull & JMJ Productions v. Greg LaPlant and Chris Kolaskos
411 S.W.3d 129 (Court of Appeals of Texas, 2013)
Kelly Investment, Inc. v. Basic Capital Management, Inc.
85 S.W.3d 371 (Court of Appeals of Texas, 2002)
TV Azteca v. Ruiz
490 S.W.3d 29 (Texas Supreme Court, 2016)
Old Republic Nat'l Title Ins. Co. v. Bell
549 S.W.3d 550 (Texas Supreme Court, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
John Feeney v. Morfin Capital Group LLC and Medone Texas MSO, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/john-feeney-v-morfin-capital-group-llc-and-medone-texas-mso-llc-texapp-2024.